Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 17, 2016. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) under the company's US Deferred Performance Plan.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per ADS | Total Volume (ADSs) |
|---|---|---|---|
| October 13, 2016 | American Depositary Shares (ADSs) | $46.1526 | 574.514 |
Note: Total volume is the aggregate of two separate transactions reported in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of ADSs by executives following the re-investment of dividends paid on October 13, 2016.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a statutory disclosure of specific transactions executed on the New York Stock Exchange (XNYS).
Key Facts for Investor Verification
- Transaction Nature: Acquisitions were made via dividend re-investment, not open market purchases.
- Executives Involved: Dr. M M Slaoui (Chairman, Global Vaccines) and Mr. D E Troy (SVP & General Counsel).
- Share Price: The acquisition price was fixed at $46.1526 per ADS for both transactions.
- Volume Breakdown: Dr. Slaoui acquired 244.955 ADSs; Mr. Troy acquired 329.559 ADSs.